Although real world evidence (RWE) is a hot topic in pharma right now, many still question whether it is acceptable to be used in regulatory decision making.
A new study has found that blood thinning drugs improve outcomes for all heart failure patients, regardless of whether they already have atrial fibrillation (AF).